Additional file 1 of Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination
Creators: name: Martín Pérez, Carla
name: Aguilar, Ruth
name: Jiménez, Alfons
name: Salmerón, Gemma
name: Canyelles, Mar
name: Rubio, Rocío
name: Vidal, Marta
name: Cuamba, Inocencia
name: Barrios, Diana
name: Díaz, Natalia
name: Santano, Rebeca
name: Serra, Pau
name: Santamaria, Pere
name: Izquierdo, Luis
name: Trilla, Antoni
name: Vilella, Anna
name: Barroso, Sonia
name: Tortajada, Marta
name: García-Basteiro, Alberto L.
name: Moncunill, Gemma
name: Dobaño, Carlota
Publisher: name: figshare
Year: 2024
Subjects: subject: Immunology
subject: FOS: Clinical medicine

description: Additional file 1. Correlates of protection and determinants of SARS-CoV-2 breakthroughs one year after third dose vaccination. Supplementary Figure 1. Comparison of antibody levels against S from Delta and Wuhan variants following hybrid immunity or vaccination alone. Supplementary Figure 2. Evolution and comparison of IgM levels following hybrid immunity or vaccination alone. Supplementary Figure 3. Evolution and comparison of antibody levels after booster vaccination according to the timing of the last SARS-CoV-2 infection in individuals vaccinated with 3 doses. Supplementary Figure 4. Evolution and comparison of IgM levels after booster vaccination according to the timing of the last SARS-CoV-2 infection in individuals vaccinated with 3 doses. Supplementary Figure 5. Comparison of antibody levels against S from Delta and Omicron variants after booster vaccination according to last SARS-CoV-2 infection in individuals vaccinated with 3 doses. Supplementary Figure 6. Linear regression analysis of the association of several factors with M24 IgG antibody levels in infected individuals vaccinated with 3 doses. Supplementary Figure 7. Evolution and comparison of antibody levels after primary vaccination with BNT162b2 or mRNA-1273 followed by booster vaccination with mRNA-1273. Supplementary Figure 8. Comparison of antibody levels against S from Delta and Omicron variants after primary vaccination with BNT162b2 or mRNA-1273 followed by booster vaccination with mRNA-1273. Supplementary Figure 9. Linear regression analysis of the association of several factors with M24 IgG levels in naïve individuals vaccinated with 3 doses. Supplementary Figure 10. Association of IgA levels at M24 with post-M24 breakthrough infections. Supplementary Figure 11. Predicted risk of breakthrough infection as a function of IgG antibody levels measured at M24. Supplementary Figure 12. Correlations between the different IgG, IgA and IgM antibody levels at M24. Supplementary Figure 13. Penalized Cox regression model to identify non-collinear antibodies highly associated with protection against breakthrough infection. Supplementary Figure 14. Heatmap of hierarchical clustering of study participants based on antibody levels at M24. Supplementary Figure 15. Directed acyclic graph (DAG) which reports our causal assumptions for generating the models to assess the total effect of a given factor on antibody levels at M24 (MFI) on naïve and infected individuals with 3 doses. Supplementary Figure 16. Directed acyclic graph (DAG) which reports our causal assumptions for generating the models to assess the total effect of a given factor on antibody levels at M24 (MFI) on naïve individuals with 3 doses. Supplementary Figure 17. Directed acyclic graph (DAG) which reports our causal assumptions for generating the models to assess the total effect of a given factor on antibody levels at M24 (MFI) on infected individuals with 3 doses. Supplementary Figure 18. Directed acyclic graph (DAG) which reports our causal assumptions for generating the models to assess the effect of booster vaccination (third dose) on antibody levels at M24 (MFI). Supplementary Figure 19. Directed acyclic graph (DAG) which reports our causal assumptions for generating the models to assess the total effect of several factors on breakthrough infection post-M24 on individuals vaccinated with 3 doses. Supplementary Figure 20. Directed acyclic graph (DAG) which reports our causal assumptions for generating the models to assess the total effect of several factors on breakthrough infection post-M24 on individuals vaccinated with 2 or 3 doses. Supplementary Table 1. Seropositivity status of study participants at M24. Supplementary Table 2. Summary of linear regression models to assess the association of a third dose of mRNA vaccine with IgG levels as compared to two doses. Supplementary Table 3. Summary of univariable Cox Regression models for the association of antibody levels with breakthrough infection in individuals vaccinated with two or three doses of mRNA vaccine. Supplementary Table 4. Summary of univariable Cox Regression models to assess the association between several clinicodemographic factors with breakthrough infection in individuals vaccinated with two or three doses of mRNA vaccine.